Bavarian Nordic 8/22/2024 Earnings Report

Bavarian Nordic EPS Results

• Actual EPS: $0.16
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Bavarian Nordic Revenue Results

• Actual Revenue: $205.99 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bavarian Nordic Announcement Details

• Date: 8/22/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Bavarian Nordic (OTCMKTS:BVNRY) A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.